Ethics statement The animal study was reviewed and approved by Xiangya Hospital Central South University
Gorrab A, Pagano A, Ayed K, Chebil M, Derouiche A, Kovacic H, et al
This study suggests that liraglutide may effectively reduce body weight and mitigate hyperphagia caused by MC4R deficiency, providing a basis for its potential therapeutic application in patients with MC4R -deficient obesity
Branded versions of semaglutide and tirzepatide such as Wegovy, Ozempic, or Zepbound undergo extensive clinical trials and FDA review for safety, efficacy, and consistency
4.8 Avg Rating 168 total reviews 100% 4+ Stars of top 10 7 Accept Insurance confirmed of 10 8 Offer Telehealth confirmed of 10 Our rankings are based on a weighted scoring system that considers multiple factors